PD-1 is an immune inhibitory receptor that is expressed on activated T and B cells and regulates immune responses to tumor antigens and autoantigens. Engagement of PD-1 on an adjacent cell by either of its ligands, PD-L1 or PD-L2, inhibits TCR signaling and TCR-mediated proliferation, transcriptional activation, and cytokine production. As a result, therapeutic antibodies designed to inhibit the PD-1/PD-L1 interaction are showing promising results in clinical trials for the treatment of a variety of cancers.
To provide a screening assay for identifying small and large molecule PD1 and PDL1 binding interaction blockage inhibitors, with the goal of eventually studying immune responses to aid in the discovery of novel immunotherapies to combat cancer.
PD1-PDL1
Human PD1, human PDL1
PD1: PDCD1, CD279, Programmed cell death protein 1
PDL1: B7 homolog 1, CD274, Programmed cell death 1 ligand 1
HTRF Assay
| Compounds | IC50 (nM) |
|---|---|
| PD1/PDL1 Inhibitor 1 (CAS#1675201-83-8) | 72.1 |
Malvern, PA, USA
More information can be found on our website Immune Checkpoint Assays
Reference compound inhibition of PD1-PDL1
Sample data showing reference compound inhibition of PD1-PDL1 binding interaction